NeuroScientific Biopharmaceuticals (ASX:NSB) confirmed that the clinical preparation for the first patient to receive the first of four treatments, under the special access program in fistulising Crohn's disease, began, according to a Friday ASX filing.
It said it had progressed the proposed acquisition of the StemSmart patented stem cell technology from Isopogen WA.
The treatments will begin on or around June 2, with evaluation to be conducted over eight to ten weeks. Fistulas are one of the most severe complications associated with Crohn's disease and are challenging to treat, the filing noted.
The first patient, along with another three patients, will together form the first cohort of patients tested under the program.
Early indications from a phase two trial in refractory Crohn's disease suggest that StemSmart technology is efficacious and safe, per the filing. If the program is successful, it will progress to a phase 1/2 clinical trial.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。